PaTiENTS aNd METHodS Patients
Including the two patients previously reported 17 , 20 individuals underwent muscle biopsy from their quadriceps or biceps brachii muscle to determine their susceptibility to MH. They were classified into an accelerated group and a non-accelerated group using the CICR rate test according to the protocol developed by Endo et al 18 . Their characteristics and results from the CICR rate test are summarised in Table 1 . The accelerated group included two individuals carrying an RYR1 mutation and two patients who had experienced an MH episode (CGS 5-6). Case no. 1 had a C>G point mutation in RYR1 exon 101 at position 14512. Case no. 2 had a C>T point mutation in RYR1 exon 47 at position 7522 and the pathologic diagnosis was myopathic changes with some fibres exhibiting cores or core-like structures, type 1 fibre predominance and type 2b fibredeficiency 10, 17 . The non-accelerated group did not include individuals with muscle disease or anyone who reported a previous MH episode.
This study was investigated by using surplus muscle after the CICR rate test. Prior to the study, written informed consent was obtained from the individuals and their families and this study was approved by the ethics committee of Hiroshima University.
Skinned fibres
Effects of propofol on CiCR by using skinned fibres, we measured the effects of propofol on Ca 2+ release. Namely, purified Thin bundles of intact fibres were isolated from the biopsied specimens. To destroy the semipermeability of the surface membrane, but not that of the sarcoplasmic reticulum (SR), fibres were treated with 50 µg.ml -1 saponin for 30 minutes. Two or three fibres were tied together with a single silk thread and connected to a strain gauge transducer (N-3193, Capto, Norway) and an amplifier (dSa-601B, Minebea, Japan). Solutions used for the measurements (solution A in Table 2 ) were placed in 0.5 ml wells in an aluminum plate. The temperature of the solutions was maintained at 20°C by using circulating water underneath the plate. The SR was loaded with a fixed amount of Ca 2+ through the Ca 2+ pumps in the presence of Mg-ATP and ATP was removed to prevent re-uptake. The muscle specimens were then treated with various concentrations of propofol (0, 10, 100 and 1000 µM) with 1.0 µM Ca 2+ . In order to assay the remaining Ca 2+ in the SR, high concentrations of caffeine caused emptying of the SR Ca 2+ store (Figure 1 , A-1). The CICR rate was estimated by comparing the amount of Ca 2+ remaining in the SR to the fixed amount of Ca 2+ .
To measure baseline Ca 2+ release from the SR independent of CICR, Ca 2+ release was measured using Ca 2+ -free solution, and after the addition of 1000 µM propofol to the Ca 2+ -free solution, Ca 2+ release was again measured (Figure 1 , A-2). Ca 2+ uptake in skinned fibre experiments, we measured the effects of propofol on Ca 2+ uptake in the accelerated group. A 1.0 M propofol stock solution was diluted to 100 and 1000 µM with loading solution for testing (solution B in Table 2 ). The SR was loaded with Ca 2+ though the Ca 2+ pumps with various concentrations of propofol (0, 100 and 1000 µM) for various periods of time (0.25, 0.5, 1.0 and 2.0 minutes). The Ca 2+ content in the SR was assayed after inducing its release with a high concentration of caffeine. Uptake of Ca 2+ into the SR was estimated from the Ca 2+ content of the SR ( Figure  1B ). Values were calculated as the percentage of the control, which was taken with 0 µM propofol for two minutes.
Cell cultures
The skeletal muscle cells isolated from the patients were maintained in dulbecco's modified Eagle medium (Invitrogen, USA) supplemented with 10% heat-inactivated bovine calf serum (FBS, Sigma-Aldrich, USA) containing 1% ampicillin sodium salt, kanamycin sulphate (Sigma, USA) and amphotericin B (Invitrogen, USA), in 25 cm 2 cell culture flasks (Corning, USA) and a 5% Co 2 atmosphere at 37°C. The medium was changed every three days. After two or three weeks in culture, the cells were plated Table 2 Constituents of the solutions used to measure the Ca 2+ -induced Ca 2+ release (CICR) rate induced by propofol on 35 mm glass-bottom culture dishes with 10 mm microwells (MatTek, USA), and allowed to grow for 10 to 14 days 20 in dulbecco's modified Eagle medium with 2% FBS until the myoblasts fused to form myotubes. We used the myotubes formed by fusion of satellite cells with a fibre-like shape and multiple nuclei.
Ca 2+ imaging of myotubes Propofol
Cells were washed in HEPES-buffered salt solution (HBSS) containing 130 mM NaCl, 5.4 mM KCl, 20 mM HEPES, 2.5 mM CaCl 2 , 1 mM MgCl 2 and 5.5 mM glucose at pH 7.4. The cells were loaded with 5.0 µM Fura-2 AM (Dojindo, Japan) in HBSS for one hour at room temperature (24 to 26°C) and washed with HBSS. The cells were then stimulated alternately at 340 nm and 380 nm. Fluorescence emission at 510 nm was measured using a fluorescence microscope (Nikon, Japan). images were acquired using a cooled, high-speed digital video camera (oRCA-AG, Hamamatsu, Japan). HBSS was perfused into the sample dishes at a rate of 1.2 ml per minute at 37°C. The 1.0 M propofol stock solution in DMSo was diluted with HBSS to make the following test concentrations: 1, 3, 10, 30, 100, 300, 1000, 3000 and 5000 µM. only the cells that racted to 20 mM caffeine (Wako, Japan) with an increase in the intracellular Ca 2+ concentration were used for experiments. Propofolinduced changes in Fura-2 aM fluorescence were measured and the 340/380 nm signal ratio was figure 1: Experimental protocol used to measure the effects of propofol on Ca 2+ -induced Ca 2+ release (CICR) (A) and Ca 2+ uptake (B). Dashed lines represent the cell membrane and solid lines denote the sarcoplasmic reticulum (SR). A-1: Loading: the Ca 2+ pumps were used to load a fixed amount of Ca 2+ into the SR. Releasing: solutions with various concentration propofol and Ca 2+ were applied to induce CICR. Assay: the remaining Ca 2+ in the SR was released by addition of assay solution containing a high concentration of caffeine. A-2: Releasing: propofol and Ca 2+ -free solution were applied. B: Loading: the Ca 2+ pumps were used to load various concentration propofol and a fixed amount of Ca 2+ into the SR. Assay: the Ca 2+ in the SR was released by addition of assay solution containing a high concentration of caffeine. calculated using a Ca 2+ imaging system (Aquacosmos 2.5, Hamamatsu Photonics, Japan) within 90 minutes after washing away the excess Fura-2 AM. The dish was rinsed with HBSS for three minutes before the next dose was given. Similarly, caffeineinduced changes in Fura-2 aM fluorescence were measured using various caffeine concentrations: 0.25, 0.5, 1.0, 2.5, 5.0, 10.0 and 20.0 mM. The two fluorescence ratios were converted into Ca 2+ concentrations using a calibration curve constructed with a calibration kit (Fura-2 Calcium Imaging Calibration Kit, Invitrogen, USA).
L-type Ca 2+ channel blocker Nifedipine dissolved in DMSo was diluted with HBSS to 50 µM. Myotubes were treated with 1000 µM propofol for three minutes, which was used as the control and washed with HBSS. Subsequently, after pretreatment with 50 µM nifedipine, 1000 µM propofol was added to the solution for three minutes. Fura-2 aM fluorescence was measured and the 340/380 nm ratio was calculated using a Ca 2+ imaging system. The same procedure was performed with 10 mM caffeine.
CICR inhibitor
Procaine hydrochloride was diluted with HBSS to 10 mM. Myotubes were treated in 1000 µM propofol for three minutes, which was used as the control and washed with HBSS. Subsequently, after pretreatment with 10 mM procaine, 1000 µM propofol was added to the solution for three minutes. Fura-2 aM fluorescence was measured and the 340/380 nm ratio was calculated using a Ca 2+ imaging system. The same procedure was performed with 10 mM caffeine.
Data analysis
The changes in the ratios were calculated from the difference between the maximal response and the preceding baseline. To obtain dose-response curves, data for propofol and caffeine were normalised to the maximum response observed with 20 mM and 10 mM caffeine, respectively. Data analysis was performed using PRISM software (graphPad Software, uSa) with Excel-based templates (Microsoft, USA).
Unpaired t-tests were used to generate statistical comparisons between the accelerated group and the non-accelerated group. Values are shown as the means ± SEM. P values less than 0.05 were considered to be significant.
RESuLTS

Effects of propofol on CICR
In 1 µM Ca 2+ , an increase in the Ca 2+ release rate was observed only with 1000 µM propofol ( Figure  2) ; compared with the propofol-free condition, the rates increased by 210±5% in the accelerated group and 194±15% in the non-accelerated group. There was no significant difference between the groups.
In Ca 2+ -free solution, 1000 µM propofol increased the Ca 2+ release rate by 143±3% in the accelerated group and 127±20% in the nonaccelerated group, as compared with the propofolfree condition. The values were not significantly different between the groups. There was, however, a significant difference between the groups in the results obtained with 1.0 µM Ca 2+ and the Ca 2+ -free solution. DMSo at the same concentrations had no effect on the CICR rate.
Uptake of Ca 2+
Uptake of Ca 2+ into the SR did not change with 100 µM propofol. However, inhibition of uptake was observed with 1000 µM propofol, which was significantly different from the propofol-free condition (Figure 3) .
EC 50 for propofol
The 340/380 nm ratio did not increase when the concentration of propofol remained within 1 to 30 µM, whereas it increased significantly when the concentration was greater than 100 µM. A dose- response curve was computed by normalising the rise of the myoplasmic Ca 2+ concentration observed with each dose to the maximum response using 20 mM caffeine (Figure 4 ). The curve of the accelerated group shifted to the left of the non-accelerated group. The calculated half-maximal activation concentrations (EC 50 ) for propofol were 274.7±33.9 µM in the accelerated group and 543.6±79.5 µM in the non-accelerated group ( Table 3 ). The EC 50 values for caffeine were 3.04±0.27 mM in the accelerated group and 4.99±0.30 mM in the non-accelerated group. DMSo at the same concentrations had no effect on the 340/380 nm ratio.
L-type Ca 2+ channel blocker
The propofol-induced Ca 2+ response was inhibited with 50 µM nifedipine by 18.0±9.0% of the control response (taken with the same concentration of propofol in nifedipine-free conditions) in the accelerated group and by 21.3±6.0% in the non-accelerated group ( Figure 5 ). There was no statistical significance between the groups. However, nifedipine significantly inhibited the propofol-induced Ca 2+ response compared with the caffeine-induced Ca 2+ response. 
CICR inhibitor
The propofol-induced Ca 2+ response was inhibited with 10 mM procaine by 4.2±0.9% of the control response (taken with the same concentration of propofol in procaine-free conditions) in the accelerated group and by 7.6±4.1% of the control response in the non-accelerated group (Figure 6 ). There was no statistical significance between the groups. Compared with the results obtained with caffeine however, procaine inhibited the propofolinduced Ca 2+ response compared with caffeine. Procaine attenuated caffeine-induced Ca 2+ response by approximately 30% of the control response.
DISCUSSIoN
By investigating intracellular Ca 2+ homeostasis in human skeletal muscle, we have demonstrated that the EC 50 of propofol is much higher than the concentrations used clinically, i.e. low concentrations of propofol did not promote CICR and inhibit Ca 2+ uptake into the SR and the mode of the action of propofol differed from that of caffeine in the presence of a Ca 2+ channel blocker or CiCR inhibitor. These findings provide a possible physiologic basis for the clinical observation that propofol is safe in individuals with predisposition to MH. In addition, propofol and caffeine may interact differently with the RYR1 Ca 2+ release channel.
CICR from the SR
in skinned fibre experiments, intracellular Ca 2+ levels become equal to extracellular Ca 2+ levels by influx of extracellular fluid, namely treated solution, into the cytoplasm due to destruction of the plasma membrane function with saponin. We measured the effects of propofol on the Ca 2+ release rate in 1.0 µM Ca 2+ . Propofol at concentrations of 10 and 100 µM did not enhance Ca 2+ release, whereas 1000 µM doubled the Ca 2+ release rate compared with the propofol-free condition. only high concentrations of propofol affected RYR1-mediated Ca 2+ efflux from SR vesicles. a study of the effects of propofol on Ca 2+ regulation in swine with MHS showed that propofol at concentrations ranging from 10 to 500 µM had no effect on ryanodine receptors, whereas concentrations higher than 500 µM propofol produced a response. In addition, propofol at concentrations greater than 300 µM competed with [ 3 H]ryanodine for binding to ryanodine receptors 21 . our results involving human muscle experiments are consistent with those of the previous animal study. Thus, it appears that only high concentrations of propofol affect RYR1 as an agonist.
At the same concentration of propofol (1000 µM), we also measured Ca 2+ release from the SR in Ca 2+ -free solution to determine the degree of Ca 2+ leak from the SR that was independent of cytosolic Ca 2+ . There was a significant difference between the results observed with 1.0 µM Ca 2+ (CICR) and the Ca 2+ -free solution (Ca 2+ leak). In the presence of cytosolic Ca 2+ , Ca 2+ release rate was increased. Therefore, the increase in Ca 2+ release induced by propofol was thought to result from augmented CICR.
Uptake of Ca 2+
Ca 2+ released from the SR is taken back up into the SR via Ca 2+ pumps. We investigated Ca 2+ uptake into the SR in skinned fibres. using loading solution that included 100 µM or 1000 µM propofol, we measured changes in the amount of Ca 2+ taken up into the SR. Due to the reduced Ca 2+ influx into the SR by propofol, the amount of Ca 2+ in the SR fell. Propofol at a concentration of 1000 µM, but not 100 µM, inhibited Ca 2+ uptake. In addition, it has previously been reported that Ca 2+ -ATPase activity in the SR is inhibited by concentrations of propofol greater than 200 µM 21 , which was consistent with our results.
Muscle contraction is driven by an increase in the intracellular Ca 2+ concentration, which occurs as Ca 2+ is released from the SR through activation of ryanodine receptors. The intracellular Ca 2+ level is regulated by Ca 2+ release from and uptake into the SR. In skeletal muscle, extrusion of Ca 2+ from the cytosol occurs mainly by uptake through Ca 2+ -ATPase pumps into the SR, although some Ca 2+ are pumped out of cells via Na + /Ca 2+ exchange.
In muscles with predisposition to MH, although the Ca 2+ release rate is accelerated compared with muscles without predisposition, the Ca 2+ release rate is slower than the Ca 2+ uptake rate. Triggering by agents that cause the Ca 2+ release rate to overtake the Ca 2+ uptake rate result in an uncontrolled rise in the cytoplasmic Ca 2+ level and a clinical MH crisis. Halothane did not affect the Ca 2+ uptake rate, and the Ca 2+ uptake rate was unchanged in both MH susceptible and normal pigs 22 .
High concentrations of propofol affected Ca 2+ homeostasis, whereas propofol in low concentrations did not inhibit uptake of Ca 2+ into the SR or increase of Ca 2+ release from the SR. Thus, clinically relevant concentrations of propofol have no marked effects on CICR and Ca 2+ -ATPases, indicating that propofol should not trigger MH.
EC 50 of propofol
Propofol is used for general anaesthesia and sedation in intensive care units at clinical concentrations ranging from 2 to 6 µg/ml, equivalent to 11 to 34 µM. Because the serum-protein binding rate ranges from 97 to 98%, free propofol concentrations under these conditions are assumed to be approximately 1 µM 23 . The 340/380 nm ratio did not increase with a propofol concentration range of 1 to 30 µM. The EC 50 values for propofol in the previous two cases, which mutations were located in C-terminal or central region, were 118.1 µM and 420.5 µM respectively 17 , and those from 10 individuals with predisposition to MH (the accelerated group) in the present study ranged from 118.1 µM to 420.5 µM. The average value was 274.7 µM, which is 100-fold greater than the clinically used concentrations. The EC 50 value in the non-accelerated group was 543.6 µM. Though we could not investigate individuals with other mutations, we investigated 10 MH predisposed individuals, including two patients who had experienced a MH episode (CGS 5-6) 24 . our findings, therefore, confirm that propofol has no significant clinical effect on intracellular Ca 2+ homeostasis. Consequently, we conclude that propofol does not trigger MH.
Comparison of the accelerated and the non-accelerated groups
We found the EC 50 value of propofol in the accelerated group was approximately half of that in the non-accelerated group. Similarly, the EC 50 value of caffeine in the accelerated group was approximately half of that in the nonaccelerated group. The EC 50 value of halothane and 4-chloro-m-cresol in MHS individuals were reported to be half of those in MH-negative individuals [25] [26] [27] . MH mutations increase the extent of ryanodine receptors in the closed Ca 2+ -sensitive state and reduce the voltage dependence of activation [28] [29] [30] . MH mutations may contribute to the abnormal sensitivity to channel activation induced by propofol due to destabilisation of the closed-state of the channel. This probably contributes to the differences between the EC 50 values from the two groups.
Comparison with caffeine
Caffeine is known to be a specific activator of ryanodine receptors and is used to investigate potential interactions on the SR via Ca 2+ channels. According to previous reports [31] [32] [33] , binding of caffeine to ryanodine receptors induces conformational changes in these channels that result in increased channel sensitivity to Ca 2+ . In the presence of nifedipine, transient increases in Ca 2+ induced by propofol were remarkably attenuated, whereas those mediated by caffeine were slightly attenuated. As for skeletal muscle, dihydropyridine receptor (DHPR, L-type Ca 2+ channel) acts as a voltage sensor, and stimulates RYR1 without significant Ca 2+ influx by direct mechanical coupling of DHPR α 1 subunit with RYR1. And the Ca 2+ blocker binds to the α 1 subunit, which is involved in channel function. A previous report showed that nifedipine increases the intracellular Ca 2+ concentration by inducing the release of Ca 2+ from the SR, which involves a membrane potential-dependent mechanism 34 . In other words, nifedipine functions as a RYR1 channel opener. In the present study, transient Ca 2+ increases induced by propofol were significantly attenuated in the presence of nifedipine. Therefore, the RYR1 channels were probably opened by the nifedipine before propofol was added. our results suggest that propofol may compete for binding of ryanodine receptors with nifedipine.
Procaine inhibits CiCR activity and acts on E-C coupling subsequent to inhibition of the T-tubule voltage sensor 35 . In the presence of procaine, the effects of propofol were almost completely inhibited due to competition with procaine both on CICR and/or DHPR. In addition, a previous report showed that propofol is more sensitive to DHPR than RYR1 21 . Also, caffeine reacts on only RYR1. Thus, the mechanism by which propofol acts on RYR1 (CICR function) is likely to be different from that of caffeine. Based on the specific mechanism involved in skeletal muscle E-C coupling, our results suggest that propofol reacts on the connecting region between DHPR and RYR1.
CoNCLUSIoN
We conclude that propofol is clinically safe in individuals with predisposition to MH, as long as it is used within the recommended dosage range, and also that the mode of the action of propofol upon ryanodine receptors is likely to be different from that of caffeine.
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